MtrE Loop2-specific multiple antigenic peptide vaccine and monoclonal antibody confer complement-dependent protection against Neisseria gonorrhoeae

1. Rowley, J. et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull. World Health Organ. 97, 548–562P (2019).

   Google Scholar 

2. Lahra, M. M. et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg. Infect. Dis. 24, 735–740 (2018).

   Google Scholar 

3. van der Veen, S. Global transmission of the penA allele 60.001-containing high-level ceftriaxone-resistant gonococcal FC428 clone and antimicrobial therapy of associated cases: a review. Infect. Microb. Dis. 5, 13–20 (2023).

   Google Scholar 

4. Lan, P. T. et al. The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023. Lancet Reg. Health West. Pac. 48, 101125 (2024).

   Google Scholar 

5. Picker, M. A. et al. Notes from the field: first case in the United States of Neisseria gonorrhoeae harboring emerging mosaic penA60 allele, conferring reduced susceptibility to cefixime and ceftriaxone. Morb. Mortal. Wkly. Rep. 69, 1876–1877 (2020).

   Google Scholar 

6. Edwards, J. L., Jennings, M. P., Apicella, M. A. & Seib, K. L. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit. Rev. Microbiol. 42, 928–941 (2016).

   Google Scholar 

7. Jerse, A. E., Bash, M. C. & Russell, M. W. Vaccines against gonorrhea: current status and future challenges. Vaccine 32, 1579–1587 (2014).

   Google Scholar 

8. Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H. & Murthy, A. K. Peptide vaccine: progress and challenges. Vaccines 2, 515–536 (2014).

   Google Scholar 

9. Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201–206 (2014).

   Google Scholar 

10. Dawood, R. M. et al. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect. Dis. 19, 932 (2019).

    Google Scholar 

11. Gulati, S. et al. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog 9, e1003559 (2013).

    Google Scholar 

12. Joshi, V. G., Dighe, V. D., Thakuria, D., Malik, Y. S. & Kumar, S. Multiple antigenic peptide (MAP): a synthetic peptide dendrimer for diagnostic, antiviral and vaccine strategies for emerging and re-emerging viral diseases. Indian J. Virol. 24, 312–320 (2013).

    Google Scholar 

13. Oscherwitz, J., Yu, F. & Cease, K. B. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect. Immun. 77, 5509–5518 (2009).

    Google Scholar 

14. Sahay, B et al. Immunogenicity and efficacy of a novel multi-antigenic peptide vaccine based on cross-reactivity between feline and human immunodeficiency viruses. Viruses 11, 136 (2019).

15. Ngampasutadol, J., Rice, P. A., Walsh, M. T. & Gulati, S. Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine 24, 157–170 (2006).

    Google Scholar 

16. Gulati, S. et al. Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine. mBio 10, e02552–02519 (2019).

    Google Scholar 

17. Wang, S. et al. Gonococcal MtrE and its surface-expressed Loop 2 are immunogenic and elicit bactericidal antibodies. J. Infect. 77, 191–204 (2018).

    Google Scholar 

18. Hagman, K. E. et al. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 141, 611–622 (1995).

    Google Scholar 

19. Yang, F. & Yan, J. van der Veen S. Antibiotic resistance and treatment options for multidrug-resistant gonorrhea. Infect. Microb. Dis. 2, 67–76 (2020).

    Google Scholar 

20. Shafer, W. M., Qu, X., Waring, A. J. & Lehrer, R. I. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc. Natl. Acad. Sci. USA 95, 1829–1833 (1998).

    Google Scholar 

21. Chen, S. et al. Could dampening expression of the Neisseria gonorrhoeae mtrCDE-encoded efflux pump be a strategy to preserve currently or resurrect formerly used antibiotics to treat gonorrhea? MBio 10, 10–1128 (2019).

22. Warner, D. M., Folster, J. P., Shafer, W. M. & Jerse, A. E. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J. Infect. Dis. 196, 1804–1812 (2007).

    Google Scholar 

23. Warner, D. M., Shafer, W. M. & Jerse, A. E. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol. Microbiol. 70, 462–478 (2008).

    Google Scholar 

24. Waltmann, A. et al. Experimental genital tract infection demonstrates Neisseria gonorrhoeae MtrCDE efflux pump is not required for in vivo human infection and identifies gonococcal colonization bottleneck. PLoS Pathog 20, e1012578 (2024).

    Google Scholar 

25. Gao, L., Wang, Z. & van der Veen, S. Gonococcal adaptation to palmitic acid through farAB expression and FadD activity mutations increases in vivo fitness in a murine genital tract infection model. J. Infect. Dis. 224, 141–150 (2021).

    Google Scholar 

26. Lee, E. H. & Shafer, W. M. The farAB-encoded efflux pump mediates resistance of gonococci to long-chained antibacterial fatty acids. Mol. Microbiol. 33, 839–845 (1999).

    Google Scholar 

27. Song, S. et al. Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy. Emerg. Microbes Infect. 12, 2249124 (2023).

    Google Scholar 

28. Cai, L. et al. Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins. Oncotarget 8, 76516–76524 (2017).

    Google Scholar 

29. Berry, J. D. & Gaudet, R. G. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N. Biotechnol. 28, 489–501 (2011).

    Google Scholar 

30. de Jong, R. N. et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14, e1002344 (2016).

    Google Scholar 

31. Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260–1263 (2014).

    Google Scholar 

32. Gulati, S. et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 17, e3000323 (2019).

    Google Scholar 

33. Idusogie, E. E. et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166, 2571–2575 (2001).

    Google Scholar 

34. Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182, 73–84 (2020).

    Google Scholar 

35. Troisi, M. et al. Human monoclonal antibodies targeting subdominant meningococcal antigens confer cross-protection against gonococcus. Sci. Transl. Med. 17, eadv0969 (2025).

    Google Scholar 

36. Vezzani, G. et al. Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection. Front. Immunol. 16, 1565862 (2025).

    Google Scholar 

37. Almonacid-Mendoza, H.L. et al. Structure of the recombinant Neisseria gonorrhoeae adhesin complex protein (rNg-ACP) and generation of murine antibodies with bactericidal activity against gonococci. mSphere 3, 10–1128 (2018).

38. Jen, F. E., Semchenko, E. A., Day, C. J., Seib, K. L. & Jennings, M. P. The Neisseria gonorrhoeae methionine sulfoxide reductase (MsrA/B) is a surface exposed, immunogenic, vaccine candidate. Front. Immunol. 10, 137 (2019).

    Google Scholar 

39. Semchenko, E. A., Day, C. J. & Seib, K. L. MetQ of Neisseria gonorrhoeae is a surface-expressed antigen that elicits bactericidal and functional blocking antibodies. Infect. Immun. 85, e00898–00816 (2017).

    Google Scholar 

40. Zielke, R. A. et al. Proteomics-driven antigen discovery for development of vaccines against gonorrhea. Mol. Cell. Proteom. 15, 2338–2355 (2016).

    Google Scholar 

41. Purcell, A. W., McCluskey, J. & Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404–414 (2007).

    Google Scholar 

42. Pishesha, N., Harmand, T. J. & Ploegh, H. L. A guide to antigen processing and presentation. Nat. Rev. Immunol. 22, 751–764 (2022).

    Google Scholar 

43. Cerutti, A., Cols, M. & Puga, I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol. 13, 118–132 (2013).

    Google Scholar 

44. Sharp, T. H. et al. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. Proc. Natl. Acad. Sci. USA 116, 11900–11905 (2019).

    Google Scholar 

45. Barr, T. A., Brown, S., Mastroeni, P. & Gray, D. TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J. Immunol. 185, 2783–2789 (2010).

    Google Scholar 

46. Cravens, M. P., Alugupalli, A. S., Sandilya, V. K., McGeady, S. J. & Alugupalli, K. R. The immunoglobulin M response to pneumococcal polysaccharide vaccine is sufficient for conferring immunity. J. Infect. Dis. 226, 1852–1856 (2022).

    Google Scholar 

47. Crotty, S. A brief history of T cell help to B cells. Nat. Rev. Immunol. 15, 185–189 (2015).

    Google Scholar 

48. Amanna, I. J. & Slifka, M. K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236, 125–138 (2010).

    Google Scholar 

49. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597–1608 (2013).

    Google Scholar 

50. Wang, G. et al. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol. Cell 63, 135–145 (2016).

    Google Scholar 

51. Kojouharova, M., Reid, K. & Gadjeva, M. New insights into the molecular mechanisms of classical complement activation. Mol. Immunol. 47, 2154–2160 (2010).

    Google Scholar 

52. Bindon, C. I., Hale, G., Brüggemann, M. & Waldmann, H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168, 127–142 (1988).

    Google Scholar 

53. Tam, J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 85, 5409–5413 (1988).

    Google Scholar 

Download references